Quick summary
Relora is a proprietary blend of botanical extracts derived from the barks of Magnolia officinalis and Phellodendron amurense. It is commonly marketed to support sleep, stress management, and mood balance. However, current research is limited, and publicly available clinical evidence does not firmly establish its efficacy or safety profile. It remains an investigational supplement with pending research status.
What is it?
Relora is a dietary supplement made from standardized extracts of magnolia bark (Magnolia officinalis) and phellodendron bark (Phellodendron amurense). Both plants have a history of use in traditional herbal medicine systems, often aimed at alleviating stress and promoting relaxation. Relora combines these two botanicals in a proprietary formulation intended to provide complementary effects on mood and stress-related symptoms.
How it may work in the body
Relora is believed to influence the nervous system in ways that may help reduce stress and support mood balance. The specific biological mechanisms remain unclear due to a lack of dedicated mechanistic research. Although the individual plant extracts have been subject to some preliminary studies, no conclusive data detail how the combined blend acts at a molecular or systemic level.
Limitations: Without direct clinical studies or mechanistic investigations, any claims about how Relora works should be regarded as speculative.
Common supplement forms
- Capsules
- Tablets
- Extract blends (proprietary formulations)
Typical dosage and how it is used
No agreed-upon consensus or official recommended daily intake exists for Relora. Supplied evidence does not provide specific dosage guidelines or ranges studied in clinical trials.
Note: Due to the absence of standardized dosing and limited clinical data, users should exercise caution and ideally consult healthcare professionals before initiating use.
Natural sources
- Magnolia officinalis bark
- Phellodendron amurense bark
Absorption and bioavailability
There are no available data addressing the absorption, bioavailability, or pharmacokinetics of Relora or its constituent extracts. Differences in oral supplement forms (e.g., capsules versus tablets) have not been evaluated in terms of their impact on bioavailability. Similarly, no information on dietary or drug factors that might enhance or inhibit absorption has been reported.
Potential benefits: what does the evidence say?
Stress and mood support
Relora is marketed primarily for reducing stress and supporting mood balance. However, the clinical evidence supporting these effects is currently insufficient. The research metadata and abstracts available do not include robust human clinical trials or detailed outcome data validating efficacy.
Early or preliminary trials may exist but were not supplied; therefore, any benefits should be regarded as unconfirmed.
Sleep support
Relora has also been promoted for improving sleep quality. Nevertheless, no published clinical trials or systematic reviews have been provided to substantiate these claims. The human evidence remains limited, and the effect on sleep is not established.
Side effects and safety
The supplied evidence did not specify common side effects, contraindications, or toxicity related to Relora supplementation. No safety concerns or adverse effects have been documented in the available research summaries, but this may reflect a lack of comprehensive data rather than conclusive safety.
As with any supplement, caution is advised, particularly because safety data for specific populations or long-term use are lacking.
Drug and supplement interactions
No interaction data were reported for Relora. This includes potential pharmacokinetic or pharmacodynamic interactions with medications or other supplements. Healthcare providers should be consulted if Relora is being considered alongside other treatments.
Who should be careful?
Due to limited safety information, individuals who are pregnant, breastfeeding, have known medical conditions, take prescription medications, or are planning surgery should exercise caution and seek medical advice before using Relora.
Pregnancy, breastfeeding and special populations
No specific safety data or usage guidance have been supplied for pregnant or breastfeeding women or other special populations. The absence of evidence means that healthcare professionals should be consulted in these cases before considering Relora supplementation.
Quality, standardization and what to look for
Relora is sold as a proprietary blend, but no details about the standardization of active components are provided. Consumers should look for products from reputable manufacturers that provide transparent labeling and quality control certifications, such as third-party testing for purity and potency.
Given the lack of official dosage guidelines and limited clinical evidence, product quality assurance is particularly important.
Frequently asked questions
- Is Relora approved by European health authorities? There are no EU-authorized health claims for Relora based on the supplied evidence.
- Can Relora treat anxiety or depression? There is insufficient clinical evidence to support these uses.
- What dose of Relora is recommended? No official dose or consensus exists. Consult a healthcare provider before use.
- Are there known side effects? No side effects have been documented in the supplied data, but the safety profile is not well established.
Evidence limitations
- No detailed clinical trials, systematic reviews, or meta-analyses were included in the supplied data.
- Research status remains pending, with limited publicly available evidence to support efficacy or safety.
- No official dosage recommendations or safety guidelines are currently established by regulatory bodies.
References
Disclaimer: This page is for informational purposes only and is not intended to provide medical advice. Dietary supplements such as Relora should not be used to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any new supplement, especially if you are pregnant, nursing, have existing health conditions, or take medications.
Last reviewed: June 2024